Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism

Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism is a topic covered in the Evidence-Based Medicine Guidelines.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central